Eagle Global Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Eagle Global Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-32,744	Closed	-$360K	–	429
2017 Q2	$360K	Sell	32,744 -28,666	-47%	-$287K	0.01%	270
2017 Q1	$602K	Hold	61,410	–	–	0.02%	193
2016 Q4	$663K	Hold	61,410	–	–	0.02%	178
2016 Q3	$629K	Hold	61,410	–	–	0.02%	178
2016 Q2	$802K	Hold	61,410	–	–	0.02%	156
2016 Q1	$676K	Hold	61,410	–	–	0.02%	165
2015 Q4	$565K	Hold	61,410	–	–	0.02%	196
2015 Q3	$426K	Hold	61,410	–	–	0.01%	227
2015 Q2	$603K	Hold	61,410	–	–	0.02%	188
2015 Q1	$544K	Buy	61,410 +7,810	+15%	+$62.2K	0.01%	182
2014 Q4	$470K	Buy	53,600 +13,490	+34%	+$109K	0.01%	203
2014 Q3	$276K	Buy	+40,110	New	+$240K	0.01%	268

Other funds holding SCLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eagle Global Advisors's SCLN Position: Q3 2017 in Review

Eagle Global Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 32,744 shares — an estimated $360K sold.

Eagle Global Advisors first reported a position in SCLN in Q3 2014 and held it in 12 quarters. The position peaked at $802K in Q2 2016. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

Eagle Global Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
Eagle Global Advisors sold 32,744 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $360K.
Eagle Global Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q3 2014 and held it in 12 quarters.
Eagle Global Advisors's Sciclone Pharmaceuticals Inc position peaked at $802K in Q2 2016.
129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Eagle Global Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.